Lexicon Pharmaceuticals Statistics
Total Valuation
LXRX has a market cap or net worth of $787.57 million. The enterprise value is $656.26 million.
| Market Cap | 787.57M |
| Enterprise Value | 656.26M |
Important Dates
The last earnings date was Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LXRX has 444.96 million shares outstanding. The number of shares has increased by 13.53% in one year.
| Current Share Class | 444.96M |
| Shares Outstanding | 444.96M |
| Shares Change (YoY) | +13.53% |
| Shares Change (QoQ) | +1.67% |
| Owned by Insiders (%) | 1.46% |
| Owned by Institutions (%) | 31.05% |
| Float | 218.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.55 |
| Forward PS | 60.42 |
| PB Ratio | 4.83 |
| P/TBV Ratio | 6.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.72 |
Financial Efficiency
Return on equity (ROE) is -43.91% and return on invested capital (ROIC) is -17.72%.
| Return on Equity (ROE) | -43.91% |
| Return on Assets (ROA) | -15.85% |
| Return on Invested Capital (ROIC) | -17.72% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 10.27% |
| Revenue Per Employee | $475,765 |
| Profits Per Employee | -$769,790 |
| Employee Count | 81 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +28.26% in the last 52 weeks. The beta is 1.08, so LXRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | +28.26% |
| 50-Day Moving Average | 1.81 |
| 200-Day Moving Average | 1.89 |
| Relative Strength Index (RSI) | 61.17 |
| Average Volume (20 Days) | 2,013,720 |
Short Selling Information
The latest short interest is 26.70 million, so 6.00% of the outstanding shares have been sold short.
| Short Interest | 26.70M |
| Short Previous Month | 25.83M |
| Short % of Shares Out | 6.00% |
| Short % of Float | 12.19% |
| Short Ratio (days to cover) | 8.55 |
Income Statement
In the last 12 months, LXRX had revenue of $38.54 million and -$62.35 million in losses. Loss per share was -$0.15.
| Revenue | 38.54M |
| Gross Profit | 31.82M |
| Operating Income | -56.81M |
| Pretax Income | -62.35M |
| Net Income | -62.35M |
| EBITDA | -56.39M |
| EBIT | -56.81M |
| Loss Per Share | -$0.15 |
Balance Sheet
The company has $183.20 million in cash and $51.89 million in debt, with a net cash position of $131.31 million or $0.30 per share.
| Cash & Cash Equivalents | 183.20M |
| Total Debt | 51.89M |
| Net Cash | 131.31M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | 163.85M |
| Book Value Per Share | 0.37 |
| Working Capital | 183.20M |
Cash Flow
| Operating Cash Flow | -64.99M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 424,000 |
| Net Borrowing | -7.26M |
| Free Cash Flow | -64.99M |
| FCF Per Share | -$0.15 |
Margins
Gross margin is 82.57%, with operating and profit margins of -147.42% and -161.80%.
| Gross Margin | 82.57% |
| Operating Margin | -147.42% |
| Pretax Margin | -161.80% |
| Profit Margin | -161.80% |
| EBITDA Margin | -146.32% |
| EBIT Margin | -147.42% |
| FCF Margin | n/a |
Dividends & Yields
LXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -13.53% |
| Shareholder Yield | -13.53% |
| Earnings Yield | -8.56% |
| FCF Yield | -8.21% |
Analyst Forecast
The average price target for LXRX is $4.47, which is 152.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.47 |
| Price Target Difference | 152.26% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 12.66% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 21, 2015. It was a reverse split with a ratio of 1:7.
| Last Split Date | May 21, 2015 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |